NCT06401538招募中2 期
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults With Either Classic Absence Epilepsy (With or Without Eyelid Myoclonia (EEM; Jeavons Syndrome), OR Developmental Epileptic Encephalopathy (DEE).
Bright Minds Biosciences Pty Ltd5 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年12月5日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 5
- 主要终点
- Change from baseline in seizure frequency in DEE subjects
研究概览
简要总结
The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Absence Epilepsy including Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome) as well as Developmental Epileptic Encephalopathies such as Dravet and Lennox Gastaut. The study will last up to 6 months. There will be a 1 month screening period, then up to 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 month follow-up period. There will be 6 clinic visits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have a diagnosis of Absence Epilepsy with or without eyelid myoclonia (Jeavons Syndrome) or a diagnosis of Developmental and Epileptic Encephalopathy (DEE) such as Dravet syndrome or Lennox-Gastaut syndrome or other DEE.
- •Subjects with Absence must experience at least 4 episodes of 3-4/second SWD lasting at least 3 seconds each in a 24 hour EEG during the baseline period. Those with DEE must have a typical EEG pattern for DEE on routine EEG and experience at least 4 seizures during the 4 week baseline period prior to BMB-101 administration.
- •Subjects can be male or female ages 18-65 inclusive at time of baseline.
- •Subject must have tried at least one anti-seizure medication at a recommended dose and duration and must be on a stable dose on their current anti-seizure medications for at least 4 weeks prior to baseline and remain stable throughout the study.
- •Subjectis willing and able to be compliant with diary completion, visit schedule, and study drug accountability.
- •Female subjects of childbearing potential must have a negative urine pregnancy test at baseline. Subjects of childbearing or child-fathering potential must be willing to use medically acceptable forms of birth control, which includes abstinence, while in this study and for 90 days after the last dose of study drug.
排除标准
- •Subject has current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, pulmonary hypertension, myocardial infarction or stroke, or clinically significant structural cardiac abnormality.
- •Subject has moderate or severe hepatic impairment. Asymptomatic subjects with mild hepatic impairment (elevated liver enzymes < 3x upper limit of normal (ULN) and/or elevated bilirubin <2x ULN) may be entered into the study after review and approval by the Medical Monitor in conjunction with the sponsor, in consideration of comorbidities and concomitant medications.
- •Subject has severe renal impairment (estimated glomerular filtration rate <30mL/min/1.73m2)
- •Clinically significant ECG abnormality such as QTcF >450 msec (males) or >470 msec (females)
- •Subject is receiving concomitant therapy with: fenfluramine, lorcaserin, monoamine-oxidase inhibitors, SSRIs, SNRIs, tricyclic antidepressants or other serotonergic agonists or antagonists (antipsychotics).
- •Subject is currently receiving an investigational medicinal product.
- •Subject has participated in another clinical trial within the past 30 days (calculated from that study's last scheduled visit). Participation in non-treatment trials will be reviewed by the medical monitor.
- •Subject has a history of drug or alcohol abuse within the last 12 months or a positive urine drug screen (with the exception of cannabinoids).
- •A current C-SSRS score of 4 or 5 at baseline or history of suicide attempt at any time during the past year
- •Subject has a clinically significant condition or has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to the Baseline Visit, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the subject.
研究组 & 干预措施
BMB-101
Experimental
BMB-101 10 mg/ml liquid
干预措施: BMB-101 (Drug)
结局指标
主要结局
Change from baseline in seizure frequency in DEE subjects
时间窗: 10 weeks
Seizure diary
Change from baseline in the number of generalized spike-wave discharges (GSWD) on the 24 hr EEG in Absence subjects.
时间窗: 6 weeks
24 hour EEG
次要结局
- Change from baseline in quality of life(6-10 weeks)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)GVHD, ChronicNCT04930562BioNova Pharmaceuticals (Shanghai) LTD.30
已完成
1 期
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic TumorsSolid Tumor, AdultAdvanced Solid TumorMetastatic Solid TumorNCT04761198Mereo BioPharma76
已完成
2 期
A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 DiseaseBatten DiseaseJansky-Bielschowsky DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2CLN2 DiseaseCLN2 DisorderNCT02678689BioMarin Pharmaceutical14
已完成
2 期
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple subcutaneous doses of BMN 045 (previously known as PRO045) in subjects with Duchenne muscular dystrophyDuchenne's disease1002830210029317Duchenne muscular dystrophyNL-OMON43779BioMarin Parmaceutical Inc.5
进行中（未招募）
1 期
A study to test if multiple injections of PRO045 are safe and effective in people who suffer from Duchenne muscular dystrophyDuchenne muscular dystrophy resulting from a mutation correctable by PRO045-induced DMD exon 45 skippingMedDRA version: 18.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-005040-10-FRProsensa Therapeutics BV45